NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Forecast, Price & News $0.70 +0.02 (+2.96%) (As of 10:53 AM ET) Add Compare Share Share Today's Range$0.68▼$0.7050-Day Range$0.47▼$0.9052-Week Range$0.45▼$3.74Volume24,076 shsAverage Volume273,378 shsMarket Capitalization$69.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Accelerate Diagnostics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.07% of Shares Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$139,390 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector726th out of 1,006 stocksAnalytical Instruments Industry19th out of 29 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Accelerate Diagnostics. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.07% of the outstanding shares of Accelerate Diagnostics have been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Accelerate Diagnostics has recently decreased by 6.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.Environmental SustainabilityThe Environmental Impact score for Accelerate Diagnostics is -1.62. Previous Next 1.9 News and Social Media Coverage News SentimentAccelerate Diagnostics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AXDX on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $139,390.00 in company stock.Percentage Held by Insiders42.20% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.14% of the stock of Accelerate Diagnostics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($0.59) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Accelerate Diagnostics (NASDAQ:AXDX) StockAccelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.Read More Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXDX Stock News HeadlinesMay 18, 2023 | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.comMay 12, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports First Quarter 2023 Financial ResultsMay 31, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 11, 2023 | msn.comRecap: Accelerate Diagnostics Q1 EarningsMay 11, 2023 | finance.yahoo.comAccelerate Diagnostics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comSyneos Health (SYNH) Announces a $7.1 Billion Merger AgreementMay 10, 2023 | markets.businessinsider.comAccelerate Diagnostics is about to announce its earnings — here's what Wall Street expectsMay 9, 2023 | americanbankingnews.comAccelerate Diagnostics (AXDX) Scheduled to Post Quarterly Earnings on ThursdayMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.April 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Repligen (RGEN), SurModics (SRDX) and Accelerate Diagnostics (AXDX)April 27, 2023 | finance.yahoo.comAccelerate Diagnostics scheduled call to review 2023 first quarter resultsApril 17, 2023 | finance.yahoo.comAccelerate Diagnostics, Inc.'s (NASDAQ:AXDX) 38% Jump Shows Its Popularity With InvestorsApril 4, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Accelerate Diagnostics, Inc. Decreased by Analyst (NASDAQ:AXDX)April 3, 2023 | finance.yahoo.comAccelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?April 3, 2023 | americanbankingnews.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest UpdateApril 1, 2023 | finance.yahoo.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call TranscriptMarch 31, 2023 | americanbankingnews.comAccelerate Diagnostics, Inc. to Post Q1 2024 Earnings of ($0.16) Per Share, William Blair Forecasts (NASDAQ:AXDX)March 30, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 30, 2023 | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.comMarch 29, 2023 | msn.comAccelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue EstimatesMarch 29, 2023 | finance.yahoo.comAccelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 28, 2023 | markets.businessinsider.comCraig-Hallum Keeps Their Hold Rating on Accelerate Diagnostics (AXDX)March 27, 2023 | americanbankingnews.comAccelerate Diagnostics (AXDX) to Release Earnings on WednesdayMarch 15, 2023 | finance.yahoo.comAccelerate Diagnostics scheduled call to review 2022 fourth quarter and full year resultsMarch 8, 2023 | finance.yahoo.comAccelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of DirectorsFebruary 19, 2023 | marketwatch.comAllergy Diagnostics Market New Insight Report 2023: Estimated to Accelerate Industry Growth with SWOT Analysis, Top Players, and Outlook 2029February 10, 2023 | theglobeandmail.comClosing Bell: Accelerate Absolute Return Hdg Fund ETF flat on Friday (HDGE)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXDX Company Calendar Last Earnings3/29/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXDX CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees220Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,490,000.00 Net Margins-516.49% Pretax Margin-522.81% Return on EquityN/A Return on Assets-105.39% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.55 Sales & Book Value Annual Sales$12.75 million Price / Sales5.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-3.07Miscellaneous Outstanding Shares99,830,000Free Float57,703,000Market Cap$67.39 million OptionableOptionable Beta1.18 Key ExecutivesJack PhillipsPresident, Chief Executive Officer & DirectorMaya GowriHead-Operations & Senior Vice PresidentDavid PatienceChief Financial OfficerLawrence MertzChief Technology OfficerGretchen StrohmingerSenior VP, Head-Human Resources & CultureKey CompetitorsSingular Genomics SystemsNASDAQ:OMICBerkeley LightsNASDAQ:BLITelesis BioNASDAQ:DNAYRapid Micro BiosystemsNASDAQ:RPIDCue HealthNASDAQ:HLTHView All CompetitorsInsiders & InstitutionsLarry Michael MertzSold 3,480 sharesTotal: $2,505.60 ($0.72/share)Susquehanna International Group LLPSold 130,500 shares on 5/16/2023Ownership: 0.000%Jack PhillipsSold 7,940 sharesTotal: $5,478.60 ($0.69/share)David PatienceSold 1,222 sharesTotal: $843.18 ($0.69/share)Price T Rowe Associates Inc. MDSold 26,380 shares on 5/15/2023Ownership: 0.064%View All Insider TransactionsView All Institutional Transactions AXDX Stock - Frequently Asked Questions Should I buy or sell Accelerate Diagnostics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AXDX shares. View AXDX analyst ratings or view top-rated stocks. How have AXDX shares performed in 2023? Accelerate Diagnostics' stock was trading at $0.7060 at the start of the year. Since then, AXDX shares have decreased by 4.4% and is now trading at $0.6750. View the best growth stocks for 2023 here. When is Accelerate Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our AXDX earnings forecast. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its quarterly earnings data on Wednesday, March, 29th. The medical research company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $2.97 million for the quarter, compared to the consensus estimate of $3 million. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU). What is Accelerate Diagnostics' stock symbol? Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX." Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (10.29%), Tejara Capital Ltd (0.36%), Allworth Financial LP (0.15%), TCI Wealth Advisors Inc. (0.09%), Chartist Inc. CA (0.07%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Romney Humphries, Ron Price and Steven Reichling. View institutional ownership trends. How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Accelerate Diagnostics' stock price today? One share of AXDX stock can currently be purchased for approximately $0.68. How much money does Accelerate Diagnostics make? Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $67.39 million and generates $12.75 million in revenue each year. The medical research company earns $-62,490,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. How many employees does Accelerate Diagnostics have? The company employs 220 workers across the globe. How can I contact Accelerate Diagnostics? Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580. This page (NASDAQ:AXDX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.